RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Slides:

Advertisements

Similar presentations

Chapter 1: Definition and classification of CKD Kidney International Supplements Volume 3, Issue 1, Pages (January 2013) DOI: /kisup

Advertisements

Volume 68, Pages S24-S28 (July 2005)

Ischemic heart disease after renal transplantation

Volume 79, Pages S3-S8 (April 2011)

LDL cholesterol in CKD—to treat or not to treat?

Volume 54, Issue 4, Pages (October 1998)

Persistent secondary hyperparathyroidism after renal transplantation

E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P

Volume 60, Issue 6, Pages (December 2001)

Volume 67, Pages S1-S7 (June 2005)

Vitamin D Insufficiency

Volume 55, Issue 3, Pages (March 1999)

Volume 73, Issue 1, Pages 3-5 (January 2008)

Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward Adeera Levin, Paul E. Stevens Kidney International

Parathyroid hormone measurement in CKD

Volume 79, Issue 9, Pages (May 2011)

Lipopheresis in the nephrotic syndrome

Phosphorus Nutrition and the Treatment of Osteoporosis

Vitamin D deficiency and heart disease

Tilman B. Drüeke, Ziad A. Massy Kidney International

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Volume 67, Issue 2, Pages (February 2005)

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets David M. Spiegel, Kate Brady Kidney.

Volume 79, Pages S3-S8 (April 2011)

M. Fukagawa, S. Nakanishi, J.J. Kazama Kidney International

Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats Eduardo Slatopolsky, Mario Cozzolino,

Volume 65, Issue 5, Pages (May 2004)

Chapter 3: Management of progression and complications of CKD

Volume 60, Issue 6, Pages (December 2001)

Volume 76, Pages S50-S99 (August 2009)

Volume 64, Issue 2, Pages (August 2003)

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: Results of the CARE study Wajeh Y. Qunibi, Charles.

Ian H. de Boer, Rajnish Mehrotra Kidney International

Comorbidity and confounding in end-stage renal disease

A new era in phosphate binder therapy: What are the options?

The need for reliable serum parathyroid hormone measurements

Sankar D. Navaneethan, MD, MPH, Suetonia C. Palmer, MBChB, Jonathan C

Use of vitamin D in chronic kidney disease patients

Volume 87, Issue 2, Pages (February 2015)

Magnesium and the risk of all-cause and cardiac mortality in hemodialysis patients: agent provocateur or innocent bystander? Cecile Courivaud, Andrew.

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

LDL cholesterol in CKD—to treat or not to treat?

Charles R. Nolan, Wajeh Y. Qunibi Kidney International

The calcium–phosphorus in guidelines for CKD-MBD

Volume 69, Issue 3, Pages (February 2006)

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Volume 68, Pages S24-S28 (July 2005)

Persistent secondary hyperparathyroidism after renal transplantation

Volume 74, Pages S88-S93 (December 2008)

Volume 56, Pages S31-S37 (December 1999)

Volume 87, Issue 1, Pages (January 2015)

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 87, Issue 3, Pages (March 2015)

Volume 87, Issue 1, Pages (January 2015)

Volume 67, Issue 4, Pages (April 2005)

Volume 75, Issue 9, Pages (May 2009)

Nicotinamide suppresses hyperphosphatemia in hemodialysis patients

Volume 78, Issue 4, Pages (August 2010)

Fibroblast growth factor 23: the making of a hormone

Volume 54, Issue 4, Pages (October 1998)

Mediterranean diets: are they practical in the Western world?

Phosphate binders on iron basis: A new perspective?

Pablo A. Ureña Torres, Marc De Broe Kidney International

Volume 70, Issue 5, Pages (September 2006)

Ischemic heart disease after renal transplantation

Volume 54, Issue 6, Pages (January 1998)

Increased fetuin-A levels following treatment with a vitamin D analog

Volume 74, Issue 10, Pages (November 2008)

Volume 61, Issue 4, Pages (April 2002)

Presentation transcript:

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K. Burke, Maureen A. Dillon Kidney International Volume 55, Issue 1, Pages 299-307 (January 1999) DOI: 10.1046/j.1523-1755.1999.00240.x Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 1 Structure of RenaGel®, cross-linked poly(allylamine hydrochloride). Kidney International 1999 55, 299-307DOI: (10.1046/j.1523-1755.1999.00240.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 2 Effect of RenaGel® on serum phosphorus. During the treatment period with RenaGel the decrease in serum phosphorus 9.1 ± 2.4 to 6.6 ± 1.9 mg/dl was statistically significant (P 0.0001). Kidney International 1999 55, 299-307DOI: (10.1046/j.1523-1755.1999.00240.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 3 Effect of RenaGel® on serum calcium. Kidney International 1999 55, 299-307DOI: (10.1046/j.1523-1755.1999.00240.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 4 Effect of RenaGel® on Ca × P product. Kidney International 1999 55, 299-307DOI: (10.1046/j.1523-1755.1999.00240.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 5 Effect of RenaGel® on serum parathyroid hormone (PTH). At the end of the 2 week treatment, the decrease in PTH was statistically significant (P < 0.0001). After RenaGel was discontinued there was a significant increase in the levels of serum PTH (P < 0.0001). Kidney International 1999 55, 299-307DOI: (10.1046/j.1523-1755.1999.00240.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 6 Effect of RenaGel® on serum total cholesterol. Kidney International 1999 55, 299-307DOI: (10.1046/j.1523-1755.1999.00240.x) Copyright © 1999 International Society of Nephrology Terms and Conditions

Figure 7 Effect of RenaGel® on serum low density lipoprotein (LDL). The decrease in LDL was highly statistically significant (P < 0.0001). Kidney International 1999 55, 299-307DOI: (10.1046/j.1523-1755.1999.00240.x) Copyright © 1999 International Society of Nephrology Terms and Conditions